Related Experiment Video
Updated: Jul 2, 2026
09:35
Analysis of Somatic Hypermutation in the JH4 intron of Germinal Center B cells from Mouse Peyer's Patches
Published on: April 20, 2021
Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation
Alexander J A Deutsch1, Margareta Frühwirth, Ariane Aigelsreiter
1Division of Hematology, Department of Internal Medicine, Medical University Graz, Graz, Austria.
The Journal of Investigative Dermatology
|August 16, 2008
Summary
Aberrant somatic hypermutation (ASHM) was investigated in primary cutaneous marginal zone B-cell lymphoma (PCMZL). ASHM, a genetic instability mechanism, was found in most PCMZL cases, suggesting its role in disease development.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Aberrant somatic hypermutation (ASHM) is a known mechanism inducing genetic instability in diffuse large B-cell lymphoma.
- Primary cutaneous marginal zone B-cell lymphoma (PCMZL) is a type of non-Hodgkin lymphoma affecting the skin.
Purpose of the Study:
- To investigate the presence and characteristics of ASHM in primary cutaneous marginal zone B-cell lymphoma (PCMZL).
- To determine the potential role of ASHM in the pathogenesis of PCMZL.
Main Methods:
- Analysis of the mutational profile of key genes (PAX5, RhoH/TTF, cMYC, PIM1) in 11 PCMZL samples.
- Identification and characterization of sequence variants to assess for ASHM features.
Main Results:
- Seventeen sequence variants were identified in 8 out of 11 (72.7%) PCMZL cases.
- The observed mutations exhibited molecular features characteristic of ASHM.
- Two mutations, one in PIM1 and one in cMYC, resulted in amino acid substitutions with potential functional implications.
Conclusions:
- Aberrant somatic hypermutation (ASHM) is associated with primary cutaneous marginal zone B-cell lymphoma (PCMZL).
- ASHM may contribute significantly to the pathogenesis of PCMZL through mutations in regulatory and coding gene sequences.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
01:23Cells of the Adaptive Immune Response
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...